Search Results
Your search for ,OUr matches 10724 pages
Showing 201 - 250NSAIDs May Improve Survival in Postoperative ctDNA-Positive Patients With Colon Cancer
Circulating tumor DNA (ctDNA) levels may help to determine which patients with colon cancer could benefit from the addition of nonsteroidal anti-inflammatory drugs (NSAIDs), such as celecoxib, to chemotherapy following surgery, according to findings from a post hoc analysis of the CALGB/SWOG 80702...
Community Oncology Report Showcases Barriers to Therapy Access, Staffing, and Clinical Trial Participation
A report recently released by McKesson on the state of community oncology highlights the current challenges facing physicians, administrators, and clinical staff who work in community practices. The "Advancing Community Oncology Report" details these challenges as well as opportunities for growth...
Flipped Nivolumab/Ipilimumab Dosing Improves Responses, Survival, and Safety in Advanced Melanoma
The flipped dose for nivolumab at 3 mg/kg and ipilimumab at 1 mg/kg led to improved response rates and survival findings as well as lower severe immune-related toxicities compared with the standard dose of the immunotherapy combination in patients with advanced unresectable melanoma, according to...
AI Models Advance Individualized Breast Cancer Recurrence Risk Assessments
Two presentations at the 2025 San Antonio Breast Cancer Symposium (SABCS) highlighted new artificial intelligence (AI) tools and systems for improving distant recurrence risk stratification among patients with early-stage breast cancer. The first tested multimodal AI models with imaging, clinical,...
Is Menopausal Hormone Therapy Associated With Increased Breast Cancer Risk?
Using menopausal hormone therapy was not associated with an increased risk of breast cancer in women with inherited mutations in the BRCA1 or BRCA2 genes, according to the results of a matched prospective analysis presented at the 2025 San Antonio Breast Cancer Symposium (SABCS; Abstract GS3-01)....
Can Multimodal AI Models Predict Distant Recurrence Risk in Patients With Early Breast Cancer?
Multimodal artificial intelligence (AI) models using a combination of molecular, imaging, and clinical features improved the individual prognostic assessment of patients with early breast cancer's risk of distant recurrence, according to an analysis presented at the 2025 San Antonio Breast Cancer...
Sacituzumab Govitecan vs Standard of Care for Certain Endocrine Therapy–Refractory Advanced Breast Cancers
Patients with hormone receptor–positive, HER2-negative advanced breast cancers had similar progression-free survival whether they were treated with sacituzumab govitecan-hziy or standard-of-care chemotherapy as the first treatment after endocrine therapy, according to results from the phase III...
Phase III Trial Shows No Oncologic Benefit From Routine Preoperative MRI for Some Early Breast Cancers
Rates of local regional recurrence were very low for patients with early-stage triple-negative or HER2-positive breast cancer regardless of whether or not they received a breast MRI for staging and surgical planning, according to findings from the phase III Alliance A011104/ACRIN 6694 trial...
HER2CLIMB-05 Study: Tucatinib Enhances Progression-Free Survival as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer
The addition of the selective HER2 inhibitor tucatinib to trastuzumab and pertuzumab as first-line maintenance therapy significantly prolonged investigator-assessed progression-free survival in patients with HER2-positive metastatic breast cancer, according to findings presented at the 2025 San...
Abbreviated Azacitidine Regimen Improves Outcomes in Lower-Risk MDS
A multicenter trial led by investigators at The University of Texas MD Anderson Cancer Center demonstrated that a 5-day regimen of azacitidine provides the best balance of efficacy and safety for patients with lower-risk myelodysplastic syndromes (MDS). The researchers compared three abbreviated...
AI Tops Density in Predicting Breast Cancer Risk
An image-only artificial intelligence (AI) model for predicting the 5-year risk of breast cancer provided stronger and more precise risk stratification than breast density assessment, according to a news statement issued about a study presented at the annual meeting of the Radiological Society of...
Hear, Hear to ‘Advancing Geriatric Oncology: Where We Have Been and Where We Are Going’
We read with interest the commentary by Stuart Lichtman, MD, FASCO,on “Advancing Geriatric Oncology: Where We Have Been and Where We Are Going,“ in the October 25, 2025 issue of The ASCO Post.1 Dr. Lichtman outlines the challenges in delivering cancer care to the elderly population. Among these...
Christine M. Lovly, MD, PhD, FASCO, Named Head, Thoracic Oncology, at City of Hope
Christine M. Lovly, MD, PhD, FASCO, an expert on lung cancer with almost 2 decades of experience in clinical care, translational research, and academic leadership, will spearhead the new national thoracic oncology program at City of Hope in Duarte, California. In her new role, effective January 1, ...
Doublet Therapy Yields Higher Response Rates and Fewer Complications Than Standard Induction in AML
The combination of azacitidine and venetoclax led to improved efficacy outcomes with fewer complications than standard intensive induction chemotherapy as upfront treatment for patients with acute myeloid leukemia (AML), according to trial findings presented at the 2025 American Society of...
Integrating Mental Health Into Cancer Care: A Community Oncology Imperative
When Julie began chemotherapy for breast cancer, her oncologist adjusted antiemetics weekly and carefully tracked neutrophil counts. Still, no one asked about the panic attacks that kept her awake at night. She told herself this was just part of cancer. It was not until she stopped showing up for...
High Risk of Metastatic Recurrence Among Young Patients With Cancer
A new study of adolescents and young adults (AYAs) with seven common cancers reveals that nearly one in ten patients diagnosed with non-metastatic disease later develop metastatic recurrence. The information was shared in a news statement from the UC Davis Comprehensive Cancer Center. Scientists at ...
The Diagnosis I Couldn’t Deliver: An Oncologist’s Journey Between Roles
As a medical oncologist and palliative care physician, I have spent years preparing for difficult conversations. I’ve guided patients and families through the uncertainty of cancer, helped them navigate complex decisions, and sought meaning amid shifting prognoses. As an academic, I teach future...
Mount Sinai Tisch Cancer Center Receives Comprehensive Cancer Center Designation and Funding from National Cancer Institute
The Mount Sinai Tisch Cancer Center (TCC) has been named a Comprehensive Cancer Center by the National Cancer Institute (NCI), the highest designation awarded to cancer centers in the United States. This recognition places Mount Sinai among the top one percent of cancer centers nationwide and...
Eliminating Barriers to Care for Patients With Intellectual and/or Developmental Disabilities
A recent large, retrospective study by Giblon et al has found that individuals with intellectual and/or developmental disabilities face an increased risk of developing cancer, higher symptom burden once they get cancer compared with those without such disabilities, and disparities in accessing...
Montefiore Einstein Comprehensive Cancer Center Director, Physician Scientist, Edward Chu, MD, MMS, Dies at 66
Albert Einstein Collegeof Medicine and Montefiore Einstein Comprehensive Cancer Center shared news of the death of the Cancer Center’s Director, Edward Chu, MD, MMS, on November 13, 2025. The cause of death was glioma. Here is the statement: “We are deeply saddened to share the news that Dr. Ed...
One in Three Families of Children With ALL Face Financial Hardship During Treatment
A new multicenter study reports that nearly one-third of families with children undergoing chemotherapy for acute lymphoblastic leukemia (ALL) develop substantial financial hardships during the 2 years of treatment. These difficulties—defined as the inability to pay for housing, food, or utilities, ...
How AI Is Ushering in a New Era in Cancer Care
On October 30, 2025, Google Cloud held its second annual Cancer AI Symposium to explore how artificial intelligence (AI) is advancing cancer research, diagnosis, and treatment, in unparalleled ways. Held at Google’s St. John’s Terminal office in New York City, the event brought together leaders in...
Ross Levine, MD, Named Chief Scientific Officer of Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSK) announced that Ross Levine, MD, has been named MSK’s new Chief Scientific Officer (CSO). Dr. Levine previously served as Senior Vice President of Translational Research in Memorial Hospital (MH) and holds the Edward P. Evans Endowed Chair for...
Non–Total Body Irradiation Conditioning Regimen for Young Patients With MRD-Negative B-ALL
Two-year event-free survival rates were above 75% for children, adolescent, and young adult patients with B-cell acute lymphocytic leukemia (B-ALL) who had negative measurable residual disease (MRD) by next-generation sequencing prior to hematopoietic cell transplantation and who received a...
Building the Cancer Care Africa Deserves
There is something deeply moving about watching hope take shape, not as a slogan or a speech, but as people coming together to build the cancer care Africa deserves. The African Organization for Research and Training in Cancer (AORTIC) 2025 Congress in Tunisia held in November was a vivid reminder...
ASTRO Marks Former President Biden’s Prostate Cancer Treatment Milestone
The American Society for Radiation Oncology (ASTRO) congratulates former President Joe Biden on completing his course of radiation therapy, which he marked by ringing the ceremonial bell alongside his radiation oncology care team. “President Biden’s bell-ringing milestone underscores the vital role ...
Black Patients With AML Face Younger Onset and Significantly Worse Survival Outcomes
A new analysis spanning more than 3 decades of Eastern Cooperative Oncology Group and American College of Radiology Imaging Network (ECOG-ACRIN) clinical trial data demonstrates that Black patients with acute myeloid leukemia (AML) present with the disease at a significantly younger age and...
Final Overall Survival Confirms Benefit of Durvalumab Plus FLOT in Resectable Gastric and Gastroesophageal Junction Adenocarcinomas
The addition of the PD-L1–targeting monoclonal antibody durvalumab to conventional perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) resulted in a statistically significant and clinically meaningful improvement in overall survival, with benefit seen...
Final Analysis Supports Use of Durvalumab Plus BCG Infusions in High-Risk Non–Muscle-Invasive Bladder Cancer
In patients with high-risk non–muscle-invasive bladder cancer, the addition of 1 year of the PD-L1 inhibitor durvalumab to standard induction and maintenance bacillus Calmette-Guérin (BCG) infusions led to a statistically significant and clinically meaningful improvement in disease-free survival...
AACR Pediatric Cancer Progress Report Highlights Advances Made, Long-Term Survivorship Challenges, and Persistent Disparities in Care
Although treatment advances in pediatric cancers have resulted in increases in overall 5-year survival for children and adolescents diagnosed with cancer, many pediatric survivors face chronic health conditions as they age, as well as financial, social, and psychological challenges, according to...
Renuka Iyer, MD, Named New Chief Medical Officer for NCCN
The National Comprehensive Cancer Network® (NCCN®) has announced the hiring of Renuka Iyer, MD, as the new Chief Medical Officer (CMO) for the organization. Dr. Iyer has a long history of leadership and innovation in oncology. She currently serves as a Professor of Oncology for Roswell Park...
Are Glycemic Index and Load Associated With Lung Cancer Risk?
Based on the results of a population-based cohort study published in Annals of Family Medicine by Wang et al, high dietary glycemic index is linked to increased risks of lung cancer, non–small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), whereas glycemic load is inversely associated ...
AYA Cancers: Survival for Metastatic Recurrence Worse Than De Novo Metastatic Disease
Almost 10% of adolescents and young adults (AYAs) diagnosed with earlier-stage cancer develop metastatic disease, and survival outcomes were found to be worse for patients who developed metastatic recurrence compared with those who had metastatic disease at initial diagnosis for almost all analyzed ...
Image-Only AI Model Outperforms Breast Density Assessment for 5-Year Breast Cancer Risk Stratification
An image-only artificial intelligence (AI) model demonstrated stronger and more precise risk stratification than breast density assessment for predicting 5-year risk for developing breast cancer, according to findings from a study presented at the 2025 Annual Meeting of the Radiological Society of...
As a Cancer Survivor, My Main Worry Now Is Affording Health Insurance
Until 3 years ago, cancer was so utterly frightening to me that I avoided discussing the disease or even mentioning the word as much as possible. I sympathized with a friend when she was diagnosed with lung cancer, but I never expected to be in her position. I’m a never-smoker, and except for a...
ASTRO Recognizes 2025 Award Recipients for Excellence in Radiation Oncology
During its recent Annual Meeting, the American Society for Radiation Oncology (ASTRO) honored the recipients of its 2025 Gold Medal awards and other prestigious distinctions. Here, The ASCO Post celebrates the achievements of these leading radiation oncology experts. Gold Medal The Gold Medal is...
How an Endowed Chair in Cord Blood Research Is Providing New Hope for Patients With High-Risk Leukemia
In 2016, Filippo Milano, MD, PhD, Associate Professor, Translational Science and Therapeutics Division, and Director of the Cord Blood Transplant Program at Fred Hutchinson Cancer Center in Seattle, published the results of his landmark study investigating whether an alternative stem cell donor...
Memorial Sloan Kettering Names Recipients of 2025 Paul Marks Prize for Cancer Research
Memorial Sloan Kettering Cancer Center (MSK) will award three cancer researchers with this year’s Paul Marks Prize for Cancer Research. The prize, named in honor of former MSK president Paul Marks, MD, recognizes a new generation of leaders who are making significant contributions to the...
Project DISARM: New Cancer Mission Emphasizes Risk Assessment and Early Detection of Ovarian Cancer
Often referred to as a “silent killer,” ovarian cancer is the most lethal of female cancers. Issues of late detection and poor survival rates continue to persevere, leading to increasing levels of incidence and mortality. Data from the World Ovarian Cancer Coalition have stressed that ovarian...
Icahn School of Medicine Family Center for Caregiving Launches Website to Further Reach and Broaden Mission
Allison J. Applebaum, PhD, FAPOS, recently announced the launch of the website for the Steven S. Elbaum Family Center for Caregiving at the Icahn School of Medicine at Mount Sinai in New York (www.mountsinai.org/care/palliative-care/elbaum-center-caregiving). Dr. Applebaum is Director of the...
Proton vs Photon Radiation Therapy for Nonmetastatic Breast Cancer: Focus on Patient Perspective and Satisfaction
Health-related quality-of-life analyses for proton radiation therapy and photon radiation therapy in patients with nonmetastatic breast cancer showed similar impacts on quality of life with both treatments, according to findings from the phase III RadComp consortium trial. Shannon M. MacDonald, MD, ...
Final Analysis Supports Use of Durvalumab Plus BCG Infusions in High-Risk Non–Muscle-Invasive Bladder Cancer
In patients with high-risk non–muscle-invasive bladder cancer, the addition of 1 year of the PD-L1 inhibitor durvalumab to standard induction and maintenance bacillus Calmette-Guérin (BCG) infusions led to a statistically significant and clinically meaningful improvement in disease-free survival...
HER2-Positive Early Breast Cancer: Trastuzumab Deruxtecan Moves Into Earlier Clinical Settings
Two pivotal studies of fam-trastuzumab deruxtecan-nxki (T-DXd) in early HER2-positive breast cancer suggest this antibody-drug conjugate (targeting the HER2 protein) may be moving into the curative setting after having shown benefit in metastatic disease in multiple previous trials. The new...
Geriatric Assessment–Guided Approach to Treatment Intensity in Older Adults With Acute Myeloid Leukemia
“Pretreatment geriatric assessment in older adults with acute myeloid leukemia is feasible, can identify several functional impairments, and [can] guide the selection of treatment intensity,” resulting in low rates of early mortality, according to Vijaya R. Bhatt, MBBS, MS, of the University of...
Reducing the Barriers to Receiving CAR T-Cell Therapy for Patients With Hematologic Malignancies
Chimeric antigen receptor (CAR) T-cell therapy has transformed treatment for patients with hematologic malignancies, achieving unprecedented responses in some patients, especially those diagnosed with relapsed/refractory B-cell acute lymphocytic leukemia, non-Hodgkin lymphoma, and multiple...
ASTRO Experts Comment on the Results of the SUPREMO Trial
A large international study published by Kunkler et al in The New England Journal of Medicine examined whether chest wall radiation therapy after mastectomy improves survival for patients with early-stage breast cancer. The study, known as the SUPREMO trial, found no overall survival difference...
Could Opportunistic Salpingectomy Prevent Ovarian Cancer in Postreproductive Women?
Known as “the silent killer” due to its lack of symptoms and reliable screening tests, ovarian cancer remains one of the deadliest gynecologic cancers, claiming more than 12,000 lives annually. At a recent meeting, experts said that performing a single preventive procedure within general surgery...
Melanoma Cancer Cluster Found in Parts of Pennsylvania
Researchers have identified a melanoma cancer cluster in 15 counties in Pennsylvania near or containing cultivated croplands, according to findings published in JCO Clinical Cancer Informatics. The research highlights that sunlight and areas of higher herbicide use may contribute to these...
New Computational Tool Shows Strong Accuracy in Predicting Cancer Drug Targets
Using a computational tool, DeepTarget, physicians were able to predict both primary and secondary targets of small-molecule agents for cancer treatment, according to findings from a study published in npj Precision Oncology. The study authors suggest that this represents a potentially significant...
New Study Explores Why Male Patients With AML May Have Worse Outcomes
New research has ruled out hormone signaling as the reason why men with acute myeloid leukemia (AML) tend to have poorer outcomes than women, even when treated with the same intensive chemotherapy—a finding that helps refine future research and could influence clinical trial design. The...
